论文部分内容阅读
本月全球药品研发进展取得成效的药物共有36个,较上月减少15个。进入注册阶段的有16个,较上月减少14个。其中,5个为全球首次注册的药品,在新市场补充注册的为11个。进入注册前阶段的有9个,较上月减少5个。进入Ⅲ期临床研究阶段的有11个,较上月增加4个。5其中,抗肿瘤药0以13个高居榜首。神经系统6个,位1列次席。消化系统、免疫调节剂和内分泌及代谢调节用药各3个,并列第三。本月生物技-术药(物共15个,占比约
There were 36 drugs that made progress in global pharmaceutical research and development this month, a decrease of 15 from the previous month. There were 16 registrations, 14 less than the previous month. Among them, 5 are the first drugs registered in the world and 11 are newly registered in the new market. There were nine pre-registration stages, down five from the previous month. There were 11 clinical trials entering stage III, an increase of 4 from the previous month. Among them, antitumor drugs 0 topped the list of 13. Nervous system 6, bit 1 second place. Digestive system, immunomodulator and endocrine and metabolic regulation of the three drugs, tied for the third. This month biotech - medicine (a total of 15, accounting for about